Publications
Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings.
2020
Nat Med
Gupta RK, Calderwood CJ, Yavlinsky A, et al.
DOI:
10.1038/s41591-020-1076-0
Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation.
2020
Respir Med
Schildkraut JA, Gallagher J, Morimoto K, et al.
DOI:
10.1016/j.rmed.2020.106164
Management of drug toxicity in M. avium complex pulmonary disease - an expert panel survey.
2020
Clin Infect Dis
van Ingen J, Aliberti S, Andrejak C, et al.
DOI:
10.1093/cid/ciaa1361
Non-tuberculous mycobacterial lung disease in patients with bronchiectasis: perceived risk, severity and guideline adherence in a European physician survey.
2020
BMJ Open Respir Res
Wagner D, van Ingen J, van der Laan R, et al.
DOI:
10.1136/bmjresp-2019-000498
COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study.
2020
Lancet Child Adolesc Health
Götzinger F, Santiago-García B, Noguera-Julián A, et al.
DOI:
10.1016/S2352-4642(20)30177-2
Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine.
2020
Int J Tuberc Lung Dis
Butov D, Lange C, Heyckendorf J, et al.
DOI:
10.5588/ijtld.19.0508
Performance of immune-based and microbiological tests in children with tuberculosis meningitis in Europe: a multicentre Paediatric Tuberculosis Network European Trials Group (ptbnet) study.
2020
Eur Respir J
Basu Roy R, Thee S, Blázquez-Gamero D, et al.
DOI:
10.1183/13993003.02004-2019
The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation.
2019
Eur Respir J
van Leth F, Brinkmann F, Cirillo DM, et al.
DOI:
10.1183/13993003.02089-2018
Burden and Characteristics of the Comorbidity Tuberculosis-Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study.
2019
Open Forum Infect Dis
Sane Schepisi M, Navarra A, Altet Gomez MN, et al.
DOI:
10.1093/ofid/ofy337
Tuberculosis disease in children and adolescents on therapy with anti-tumor necrosis factor-alpha agents: a collaborative, multi-centre ptbnet study.
2019
Clin Infect Dis
Noguera-Julian A, Calzada-HernÁndez J, Brinkmann F, et al.
DOI:
10.1093/cid/ciz1138
Clofazimine does not lead to significant QT interval prolongation: a multicentre study.
2018
Eur Respir J
Zweijpfenning SMH, van Groningen H, van Ingen J, et al.
DOI:
10.1183/13993003.01386-2018
Use of Xpert MTB/RIF Ultra assays among paediatric tuberculosis experts in Europe.
2018
Eur Respir J
Villanueva P, Neth O, Ritz N, et al.
DOI:
10.1183/13993003.00346-2018
Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.
2018
Eur Respir J
van Ingen J, Aksamit T, Andrejak C, et al.
DOI:
10.1183/13993003.00170-2018
Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries.
2018
Am J Respir Crit Care Med
Günther G, van Leth F, Alexandru S, et al.
DOI:
10.1164/rccm.201710-2141OC
QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.
2018
Eur Respir J
Guglielmetti L, Tiberi S, Burman M, et al.
DOI:
10.1183/13993003.00537-2018